Name | Type | Posted | Actions |
|---|---|---|---|
https://health.mil/PandT | LINK | Nov 18, 2025 | |
Price Appendix FAQ NAD.pdf | Nov 18, 2025 | ||
DoD Formulary Placement of FDA Newly Approved Drugs.pdf | Nov 18, 2025 | ||
Price List - Vyscoxa - Pain Agents - NSAID.xlsx | XLSX | Nov 18, 2025 | |
Price List - Tonmya - SMRs and Comb - TCA.xlsx | XLSX | Nov 18, 2025 | |
Price List - Rhapsido - Atopy - NA.xlsx | XLSX | Nov 18, 2025 | |
Price List - Palsonify - Endocrine Agents Misc - NA.xlsx | XLSX | Nov 18, 2025 | |
Price List - Lynkuet - Gynecological Agents Misc- NA.xlsx | XLSX | Nov 18, 2025 | |
Price List - Jascayd - Pulmonary-1- Idiopathic PF.xlsx | XLSX | Nov 18, 2025 | |
RFQ HT9402-26-Q-9102 NAD.pdf | Nov 18, 2025 |
Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
Contact and place of performance
Stephanie Erpelding
San Antonio, TX 78230
USA
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical e...
View morea. Jascayd - Pulmonary-1 Agents - Idiopathic PF
b. Lynkuet - Gynecological Agents Misc- NA
c. Palsonify - Endocrine Agents Misc - NA
d. Rhapsido - Atopy - NA
e. Tonmya - Skeletal Muscle Relaxants and Comb - TCA
f. Vyscoxa - Pain Agents - NSAID
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9102.
Pre-quotation teleconference is on November 20, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
The Defense Health Agency (DHA) Aurora has issued solicitation HT9402-26-Q-9102 to establish an effective and integrated pharmacy benefits program for the Military Health System. This requirement involves the selection and purchase of pharmaceutical agents in accordance with 10 U.S.C. § 1074g and 32 CFR Section 199.21. Under this program, the Department of Defense (DoD) Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost effectiveness of drugs to determine their classification as generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary. The DHA may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) based on these clinical reviews.
The current solicitation focuses on newly approved drugs for review during the February 2026 P&T Committee meeting, including Jascayd, Lynkuet, Palsonify, Rhapsido, Tonmya, and Vyscoxa. These agents cover therapeutic classes such as pulmonary-1 agents, gynecological agents, endocrine agents, atopy treatments, skeletal muscle relaxants, and pain agents. Performance is centered in San Antonio, Texas, under NAICS 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals.
The response deadline for this solicitation is December 9, 2025. A pre-quotation teleconference is scheduled for November 20, 2025, to discuss the requirements and the submission process. Clinical questions must be submitted via email to the primary point of contact, Stephanie Erpelding, by the date specified in the request for quotation. Documentation associated with this notice includes 10 attachments, such as the RFQ, price appendices, and specific price lists for the reviewed medications.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.